NSE: LALPATHLAB | BSE: 539524

Expensive Rocket

Download real time

1945.10 -19.10 (-0.97%)

Near 52W High of ₹2038.60

257.7K NSE+BSE Volume

NSE 07 Oct, 2026 3:31 PM (IST)

32,648.3

Market Cap

Market Leader

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Search Inside the pdf :

Dr. Lal Pathlabs Ltd.

24 Sep 2026

1945.10

-0.97%

Acquisition aids geographic diversification, test menu expansion

Buy: Dr. Lal Pathlabs Ltd.

Target

Emkay

DLPL has announced the acquisition of SN Genelab—a B2B diagnostics operator focused on advanced genomics and molecular pathology testing—for Rs1.68bn (70% stake), thus valuing the company at ~16x FY26 EV/EBITDA.

Dr. Lal Pathlabs has gained 43.84% in the last 6 Months

Dr. Lal Pathlabs Ltd.

26 Jul 2026

1945.10

-0.97%

Spurt in high-value testing boosts performance; valuation pricey

Hold: Dr. Lal Pathlabs Ltd.

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q1FY27 performance was a beat on all fronts. The benefits of network additions are now kicking in, with patient volumes growing a strong 8.2% YoY and sample volumes up 10.7%.

Dr. Lal Pathlabs Ltd. has an average target of 1752.75 from 4 brokers.

Dr. Lal Pathlabs Ltd.

09 Jun 2026

1945.10

-0.97%

US NDR KTAs – Secular growth trends reaffirmed

Buy: Dr. Lal Pathlabs Ltd.

Emkay

We hosted the senior management (CEO, CFO) of Dr Lal Pathlabs (DLPL) for a non-deal road show (NDR), meeting long only funds across multiple cities in the US.

Dr. Lal Pathlabs Ltd. is trading above all available SMAs

Dr. Lal Pathlabs Ltd.

01 May 2026

1945.10

-0.97%

Strong quarter; upbeat FY27 guidance

Buy: Dr. Lal Pathlabs Ltd.

Emkay

DLPL delivered a strong Q4FY26 print, with revenue growing 17% YoY majorly on the back of volume growth (sample/patient: 13%/8%).

Dr. Lal Pathlabs Ltd. has an average target of 1752.75 from 4 brokers.

Dr. Lal Pathlabs Ltd.

13 Apr 2026

1945.10

-0.97%

Expanding Access to Advanced Diagnostics

Buy: Dr. Lal Pathlabs Ltd.

FundsIndia

Volume-Led Growth. Patient volumes recovering steadily. Expansion in Tier 2/3/4 markets. Increased tests per patient.

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 2100.0 on 24 Sep, 2026.

Dr. Lal Pathlabs Ltd.

17 Feb 2026

1945.10

-0.97%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Geojit BNP Paribas

EBITDA rose 16.4% YoY to Rs. 179cr, and the margin expanded 140 basis points (bps) YoY to 27.2%, driven by sustained volume growth, network expansion and a favourable mix, combined with the efficient hub-and-spoke model and technology...

Dr. Lal Pathlabs Ltd. is trading above all available SMAs

Dr. Lal Pathlabs Ltd.

02 Sep 2025

1945.10

-0.97%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Dr Lal PathLabs Ltd (DLPL) provides diagnostic tests and services globally. As of December 2024, DLPL had 280 clinical laboratories, including a national reference lab...